This is from a 2020 article, which JJ Chen was an author:
However, currently available transcriptome-wide m6A-seq methods often need a large amount of RNA material (e.g., >20 μg total RNA), thus it is difficult to conduct m6A-seq for a large cohort of patients due to the limitation in primary patient samples. Therefore, much improved m6A-seq technologies that need much less RNA material and provide base-resolution m6A profiles are urgently needed. With such improved m6A-seq technologies, we can conduct m6A profiling with precious primary patient material or even with limited primary CSCs or TICs; the m6A profiles/signatures of certain particular transcripts or transcript loci could be identified as biomarkers for early cancer diagnosis, cancer classification, outcome prediction, and risk stratification. Besides cancer cells, cell-free circulating RNA (cfRNA) collected from plasma of cancer patients could also be used for m6A-seq, and particular m6A signatures could be used as biomarkers in clinic application.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141420/
General Comments / Chat, page-4122
-
- There are more pages in this discussion • 7,107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M |
Open | High | Low | Value | Volume |
$1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1996 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 1305 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1996 | 1.605 |
2 | 4387 | 1.600 |
1 | 31000 | 1.590 |
1 | 10000 | 1.585 |
2 | 8233 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.680 | 1305 | 2 |
1.690 | 585 | 1 |
1.700 | 17181 | 1 |
1.750 | 30400 | 2 |
1.755 | 990 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |